A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice

Vaccine

Volumn 31, Issue 8, 2013, Pages 1197-1203

  Buchmann, Pascale ^a   Dembek, Claudia ^d,e   Kuklick, Larissa ^a   Jäger, Clemens ^d   Tedjokusumo, Raindy ^b,d,e   von Freyend, Miriam John ^b,c   Drebber, Uta ^b   Janowicz, Zbigniew ^a   Melber, Karl ^a   Protzer, Ulrike ^d,e  

^a Rhein Biotech   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d German Center for Infection Research   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

HBV; ISCOMATRIX adjuvant; Protein vaccine; T cells

Indexed keywords

GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; INTERLEUKIN 2; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS B; HUMORAL IMMUNITY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; TRANSGENIC MOUSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CYTOKINES; DRUG COMBINATIONS; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHOLIPIDS; SAPONINS; SPLEEN; TREATMENT OUTCOME;

EID: 84873088935     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.074     Document Type: Article

References (39)

1. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5(March (3)):215-229.
2. Bertoletti A., Ferrari C., Fiaccadori F., Penna A., Margolskee R., Schlicht H.J., et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991, 88(December (23)):10445-10449.
3. Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995, 181(March (3)):1047-1058.
4. Penna A., Chisari F.V., Bertoletti A., Missale G., Fowler P., Giuberti T., et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991, 174(December (6)):1565-1570.
5. Tan A.T., Loggi E., Boni C., Chia A., Gehring A.J., Sastry K.S., et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol 2008, 82(November (22)):10986-10997.
6. Protzer U., Maini M.K., Knolle P.A. Living in the liver: hepatic infections. Nat Rev Immunol 2012, 12(March (3)):201-213.
7. Lau G.K., Suri D., Liang R., Rigopoulou E.I., Thomas M.G., Mullerova I., et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002, 122(March (3)):614-624.
8. Ilan Y., Nagler A., Adler R., Tur-Kaspa R., Slavin S., Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993, 104(June (6)):1818-1821.
9. Schirmbeck R., Reimann J. Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Biol Chem 1999, 380(March (3)):285-291.
10. Pancholi P., Lee D.H., Liu Q., Tackney C., Taylor P., Perkus M., et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001, 33(February (2)):448-454.
11. Heintges T., Petry W., Kaldewey M., Erhardt A., Wend U.C., Gerlich W.H., et al. Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B. Dig Dis Sci 2001, 46(April (4)):901-906.
12. Dahmen A., Herzog-Hauff S., Bocher W.O., Galle P.R., Lohr H.F. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002, 66(April (4)):452-460.
13. Dienstag J.L., Stevens C.E., Bhan A.K., Szmuness W., Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen. Ann Intern Med 1982, 96(May (5)):575-579.
14. Hilleman M.R. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003, 21(December (32)):4626-4649.
15. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995, 95(January (1)):341-349.
16. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999, 30(August (2)):531-536.
17. Vandepapeliere P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26(March (10)):1375-1386.
18. Vandepapeliere P., Lau G.K., Leroux-Roels G., Horsmans Y., Gane E., Tawandee T., et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25(December (51)):8585-8597.
19. Xu D.Z., Zhao K., Guo L.M., Li L.J., Xie Q., Ren H., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008, 3(7):e2565.
20. Thimme R., Wieland S., Steiger C., Ghrayeb J., Reimann K.A., Purcell R.H., et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003, 77(January (1)):68-76.
21. Webster G.J., Reignat S., Brown D., Ogg G.S., Jones L., Seneviratne S.L., et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004, 78(June (11)):5707-5719.
22. Birnbaum F., Nassal M., Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol 1990, 64(July (7)):3319-3330.
23. Janowicz Z.A., Melber K., Merckelbach A., Jacobs E., Harford N., Comberbach M., et al. Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha. Yeast 1991, 7(July (5)):431-443.
24. Stross L., Gunther J., Gasteiger G., Asen T., Graf S., Aichler M., et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute, experimental hepatitis B virus infection. Hepatology 2012, 56(April (3)):873-883.
25. Huang L.R., Gabel Y.A., Graf S., Arzberger S., Kurts C., Heikenwalder M., et al. Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology 2012, 142(June (7)):1447e3-1450e3.
26. Guidotti L.G., Matzke B., Schaller H., Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J Virol 1995, 69(October (10)):6158-6169.
27. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19(June (6)):1513-1520.
28. Kuhober A., Pudollek H.P., Reifenberg K., Chisari F.V., Schlicht H.J., Reimann J., et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol 1996, 156(May (10)):3687-3695.
29. Schirmbeck R., Melber K., Reimann J. Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen. Int Immunol 1999, 11(July (7)):1093-1102.
30. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007, 316(April (5824)):612-616.
31. Boyle J., Eastman D., Millar C., Camuglia S., Cox J., Pearse M., et al. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 2007, 25(March (14)):2541-2544.
32. Pearse M.J., Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57(January (3)):465-474.
33. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4(January (1)):25-36.
34. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284(April (5415)):825-829.
35. Kosinska A.D., Zhang E., Lu M., Roggendorf M. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat 2010, 2010:817580.
36. Pantaleo G., Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006, 6(May (5)):417-423.
37. Kastenmuller W., Gasteiger G., Gronau J.H., Baier R., Ljapoci R., Busch D.H., et al. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 2007, 204(September (9)):2187-2198.
38. Palmowski M.J., Choi E.M., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002, 168(May (9)):4391-4398.
39. Milich D.R., Chen M., Schodel F., Peterson D.L., Jones J.E., Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci USA 1997, 94(December (26)):14648-14653.